PH26680A - Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon - Google Patents

Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon Download PDF

Info

Publication number
PH26680A
PH26680A PH39444A PH39444A PH26680A PH 26680 A PH26680 A PH 26680A PH 39444 A PH39444 A PH 39444A PH 39444 A PH39444 A PH 39444A PH 26680 A PH26680 A PH 26680A
Authority
PH
Philippines
Prior art keywords
interferon
treatment
liquid nitrogen
weeks
week
Prior art date
Application number
PH39444A
Other languages
English (en)
Inventor
Kenneth A Smiles
Daniel J Tanner
Edwin A Peets
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PH26680A publication Critical patent/PH26680A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH39444A 1988-11-01 1989-10-30 Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon PH26680A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/265,612 US4959210A (en) 1988-11-01 1988-11-01 Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon

Publications (1)

Publication Number Publication Date
PH26680A true PH26680A (en) 1992-09-15

Family

ID=23011173

Family Applications (1)

Application Number Title Priority Date Filing Date
PH39444A PH26680A (en) 1988-11-01 1989-10-30 Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon

Country Status (12)

Country Link
US (1) US4959210A (fr)
EP (2) EP0369632A1 (fr)
JP (1) JPH03503766A (fr)
KR (1) KR900701309A (fr)
AU (1) AU636312B2 (fr)
CA (1) CA2001884A1 (fr)
DK (1) DK79591A (fr)
IL (1) IL92161A0 (fr)
MY (1) MY106603A (fr)
PH (1) PH26680A (fr)
WO (1) WO1990004977A2 (fr)
ZA (1) ZA898234B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5165921A (en) * 1989-01-23 1992-11-24 National Geno Sciences, Inc. Method for treating condyloma acuminatum with interferon
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
AU9132091A (en) * 1990-12-21 1992-07-22 Schering Corporation Administering alpha interferon by oral inhalation to treat asthma and non-malignant proliferative pulmonary diseases
US6309662B1 (en) 1999-09-23 2001-10-30 Janet Buchanan Use of anti-inflammatory drugs for treatment of dermatological conditions
US7436227B2 (en) * 2003-05-02 2008-10-14 Silicon Laboratories Inc. Dual loop architecture useful for a programmable clock source and clock multiplier applications
US8778880B2 (en) 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
RU2404743C2 (ru) * 2007-03-15 2010-11-27 Государственное образовательное учреждение высшего профессионального образования "Казанский государственный медицинский университет Росздрава" Способ лечения аногенитальных бородавок
US20110218241A1 (en) * 2010-03-06 2011-09-08 Cacao Bio-Technologies, Llc Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts
CA3057768A1 (fr) 2017-03-31 2018-10-04 Accanis Biotech F&E Gmbh & Co Kg Prevention et traitement de cancer de la peau non-melanome (nmsc)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503035B1 (en) * 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
US4286690A (en) * 1979-03-05 1981-09-01 Commercial Management Corporation Escape device
JPS59175416A (ja) * 1983-03-25 1984-10-04 Sunstar Inc 皮膚および粘膜の角化異常治療用外用剤
CA1321347C (fr) * 1986-11-10 1993-08-17 David C. Munch Composition d'interferon humain leucocytaire et traitement de la peau

Also Published As

Publication number Publication date
DK79591A (da) 1991-06-14
ZA898234B (en) 1990-07-25
EP0445145A1 (fr) 1991-09-11
MY106603A (en) 1995-06-30
WO1990004977A2 (fr) 1990-05-17
AU636312B2 (en) 1993-04-29
CA2001884A1 (fr) 1990-05-01
US4959210A (en) 1990-09-25
IL92161A0 (en) 1990-07-12
DK79591D0 (da) 1991-04-30
JPH03503766A (ja) 1991-08-22
AU4524689A (en) 1990-05-28
KR900701309A (ko) 1990-12-01
EP0369632A1 (fr) 1990-05-23
WO1990004977A3 (fr) 1990-06-28

Similar Documents

Publication Publication Date Title
Petersen et al. Systemic interferon alpha-2b increases the cure rate in laser treated patients with multiple persistent genital warts: a placebo-controlled study.
US7671017B2 (en) Use of a combination of cyclosporine and pegylated interferon for treating hepatitis C (HCV)
US6638913B1 (en) Concentrated injection and infusion solution for intravenous administration
KR101126670B1 (ko) 약물 재구성 또는 희석을 위한 염화나트륨 용액
CA2542726A1 (fr) Formulations pharmaceutiques, methodes et schemas posologiques pour le traitement et pour la prevention de syndromes coronaires aigus
Douglas Jr et al. A randomized trial of combination therapy with intralesional interferon α2b and podophyllin versus podophyllin alone for the therapy of anogenital warts
PH26680A (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon
HUP0200942A2 (hu) Humán hepatitisz-C kezelése antioxidánsokkal társított ribavirint tartalmazó kombinációkkal
US5028422A (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
Ling Therapy of genital human papillomavirus infections. Part II: Methods of treatment.
US5002764A (en) Treatment of actinic keratoses with alpha2 interferon
CA1336492C (fr) Traitement des verrues genitales au moyen d'une combinaison de podophylline et d'interferon-alpha humain d'adn recombinant
CA1295243C (fr) Traitement des carcinomes de la cellule basale par l'administration dans la lesion d'interferon alpha humain recombinant
YAO et al. Antifungal therapy for treatment of cryptococcal meningitis
Varnavides et al. Intralesional interferon: ineffective in common viral warts
KR950011889B1 (ko) 정제된 재조합 사람 α-2 인터페론을 포함하는, 편평세포암 치료에 유용한 병소내 투여용 약제학적 조성물
Schulman et al. Management of viral retinitis
EP4433024A1 (fr) Formulations conservées
Nelson CHANGING TREATMENT PARADIGMS FOR HCV
Herndon Interferon 3-1a Treatment of Multiple Sclerosis
HK1107935A (en) Use of a combination of cyclosporin and pegylated interferon for treating hepatitis c (hcv)
Hoofnagle et al. Recombinant human α-interferon: A promissory note in non-A, non-B chronic hepatitis
Horsmans et al. Study in CHC patients comparing three different combination therapies with interferon a-2b (IFN) and ribavirin (rebetol): Weekly PEG-IFN (Peg-intron) versus daily IFN (intron a pen) versus standard regimen of IFN (Intron a pen)
BG61297B1 (bg) метод за лечение на нuмаn рарillома virrus инфекции